Global Journal of Hematology and Blood Transfusion  (Volume 1 Issue 1)
 Signal Transduction Therapies for Treatment of Chronic Leukemias Global Journal of Hematology and Blood Transfusion
Pages 29-41

Burçin Tezcanli Kaymaz

DOI: http://dx.doi.org/10.15379/2408-9877.2014.01.01.5
Published: 21 August 2014
Abstract
 The term signal transduction includes the interaction of external signals that are driven by hormones, growth factors, chemokines, cytokines and small molecules such as ATP in order to receive a cellular response. These responses in turn effect gene transcription and translation, cell division, survival and death upon many signaling networks related with malignancies. Since almost all diseases exhibit dysfunctional aspects of the signaling pathways, drug discovery studies in means of signal transduction therapies have an accelerating importance including chronic leukemias.
Among chronic leukemias, chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML) are being investigated extensively for abnormalities of cellular signaling pathways. This review focuses on targeting B-cell antigen receptor (BCR) signaling and Wnt/β-Catenin/LEF-1 signaling pathways and their inhibitors that provided new opportunities for development of more effective therapies for CLL. Besides this, signaling network systems such as RAS/RAF/MAPK and JAK/STAT will be discussed that contribute high oncogenic activity of BCR-ABL1 oncoprotein in CML. Finally the molecular targets in treatment duration with clinical insights will be discussed.
Keywords
 Chronic lymphocytic leukemia, Chronic myeloid leukemia, Signal transduction pathways, Treatment.
CTDL

Testimonials

SiteLock